Objectives: Long noncoding RNAs (lncRNAs) play important roles in cancer development and progression. The deregulated expression of LINC00978 has been reported in human cancers. However, the expression pattern and biological roles of LINC00978 in gastric cancer (GC) remain unclear. In this study, we investigated the potential roles and clinical value of LINC00978 in gastric cancer.
| INTRODUCTION
Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide, especially in Eastern Asia. 1, 2 The prognosis of gastric cancer remains poor since it is mostly diagnosed at advanced stage, usually accompanied by malignant proliferation, extensive invasion and distant metastasis. Therefore, the exploration of novel biomarkers is imperative for early diagnosis and effective therapies of gastric cancer.
Long noncoding RNAs (lncRNAs), defined as transcripts of more than 200 nt in length that lack protein-coding capacity, are widely transcribed in the genome. 3, 4 Compared with miRNAs that have been extensively studied, the roles of lncRNAs in human health and diseases remain to be elucidated. 5 Growing evidence suggests that lncRNAs are key players in cancer. 6, 7 Up to now, lncRNAs have been demonstrated to play vital roles in tumour initiation, progression and metastasis through modulating oncogenic and tumour-suppressing pathways. 8, 9 In addition, recent studies have indicated that a number of lncRNAs are dysregulated in gastric cancer. [10] [11] [12] [13] The aberrant expression pattern of lncRNAs can serve as biomarkers for cancer diagnosis and prognosis as well as targets for potential therapy. [14] [15] [16] However, the contributions of lncRNAs to gastric cancer remain largely unknown and suitable biomarkers still need to be explored.
LINC00978, also known as MIR4435-2HG and AK001796, is a lncRNA located in the 2q13 region of human genome. Yang et al 17 first
reported that LINC00978 was overexpressed in lung cancer tissues and cell lines. Deng et al 18 found that high level of LINC00978 predicted poor prognosis in breast cancer patients. Recently, Ke et al 19 demonstrated that a combination of circulating lncRNAs including MIR4435-2HG in plasma can serve as diagnostic markers for gastric cancer. However, the precise biological function and potential underlying mechanism of LINC00978 in gastric cancer have not been well characterized.
In this study, we determined the expression pattern of LINC00978
in gastric cancer and conducted in vitro and in vivo studies to elucidate the roles of LINC00978 in gastric cancer cell activities. Our results showed that LINC00978 expression is upregulated in gastric cancer tissues and its expression level was associated with tumour size, tumour-node-metastasis (TNM) stage and lymph node metastasis. LINC00978 promoted gastric cancer growth in vitro and in vivo and enhanced the metastatic potential of gastric cancer cells in vitro.
LINC00978 exerted its oncogenic activities through the activation of TGF-β/SMAD pathway and the induction of EMT. Our results suggest that LINC00978 is critically involved in gastric cancer progression and may serve as a potential diagnostic biomarker for gastric cancer.
| MATERIALS AND METHODS

| Microarray data analysis
Human microarray datasets GSE13911 and GSE79973 were obtained from the Gene Expression Omnibus (GEO database, http://www.ncbi.
nlm.nih.gov/geo/). The GSE13911 dataset contained the transcriptome data of 69 stomach tissues studied on an Affymetrix Human of log 2 format of normalized data was used for further analysis.
| Ethics statement
This study was performed with the approval of Ethics Review
Committee of the Affiliated People's Hospital of Jiangsu University.
Informed consents were obtained from each participants included in the study prior to sample collection. All experiments were performed in accordance with relevant regulations and guidelines. 
| Clinical samples and data collection
| Cell culture
The Results were normalized to the expression of small molecular RNA U6. The primer sequences used for qRT-PCR were presented in Table S1 . 
| RNA interference by shRNA
| Cell counting and colony formation assay
The transfected cells were seeded into 24-well plates (1 × 10 4 cells per well). The cells were trypsinized and counted every day for 6 days.
The results were plotted as cell growth curves. For colony formation assay, the transfected cells were plated into 6-well plates (1 × 10 3 cells per well) and cultured for 10 days, during which the medium was replaced every 3 days. At the end of the experiment, the colonies were washed with phosphate buffered saline (PBS), fixed with 4% paraformaldehyde for 10 minutes and stained with 0.5% crystal violet for 5 minutes. The number of visible colonies containing ≥50 cells was counted. All these experiments were performed in triplicate.
| Flow cytometric analyses of cell cycle and apoptosis
For cell cycle analysis, cells were harvested and fixed with 75% ethanol at 4°C overnight, then treated with RNase A and stained with propidium iodide (PI) for 30 minutes at 37°C. Cell cycle profiles were determined using FACSCalibur flow cytometry (BD Biosciences, San Jose, CA, USA). For the analysis of cell apoptosis, cells were collected and stained with Annexin V-FITC and PI for 15 minutes in darkness at room temperature. Cells undergoing early and late apoptosis were then quantified using flow cytometry analysis (BD Biosciences). The experiments were performed in triplicate.
| Cell migration and invasion assay
The transfected cells resuspended in 200 μL serum-free media were seeded into the upper chamber of transwell with 8 μm pore (Corning, NY, USA), which was pre-coated with (for invasion assay) or without (for migration assay) 50 μL matrigel. A total of 600 μL DMEM medium containing 10% FBS was added into the lower chamber. After incubation at 37°C with 5% CO 2 for 24 hours, cells on the upper surface were removed with a cotton swab and cells on the lower surface were fixed in paraformaldehyde for 15 minutes followed by staining with 0.2% crystal violet for 5 minutes. Cells were photographed and counted under an inverted microscope (Olympus, Tokyo, Japan). The results were mean values of 3 independent experiments.
| Protein extraction and western blot
Cells were washed and lysed in Radio-Immunoprecipitation Assay (RIPA) extraction reagent (Beyotime, Beijing, China) supplemented with a protease inhibitor cocktail solution (Roche, Indianapolis, IN, USA).
The protein samples were separated on 10% SDS-polyacrylamide gel electrophoresis and transferred to 0.22 μm PVDF membranes (Millipore, Billerica, MA, USA). After blocking with 5% non-fat milk, the membranes were incubated with specific primary antibodies against p21, poly(ADP-ribose) polymerase (PARP), caspase-3, Bcl-2, Slug,
Twist, E-cadherin, N-cadherin, Vimentin, TGF-β, p-SMAD2, SMAD2
and MMP9 antibodies (Cell Signaling Technology, Shanghai, China)
at 4°C overnight and washed extensively. After incubation with the goat anti-rabbit or anti-mouse secondary antibodies (CST), the protein bands were visualized by using chemiluminescence (Millipore). GAPDH (Sigma-Aldrich, St. Louis, MO, USA) was used as loading control.
| In vivo tumour growth assay
All procedures for animal experiments were approved by the Animal 
| Immunohistochemical staining
Tumour tissue sections were incubated with primary monoclonal antibody against Ki-67 (Cell Signaling Technology) followed by incubation with the secondary antibody for 30 minutes at room temperature. After being incubated with 3, 3′-Diaminobenzidine (3, 3′-DAB, Maxim, Fuzhou, China) for 5 minutes, the sections were counterstain with haematoxylin for 30 seconds. Finally, the sections were photographed under a TE2000 microscope (Nikon, Tokyo, Japan).
| Statistical analysis
All the data were analysed by using SPSS 22.0 software (SPSS, Chicago, IL, USA) or GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA). Differences between measured groups were assessed using Student's t test. The associations between LINC00978 expression and clinicopathological features were studied using chi-square test and Fisher's exact test. The area under the ROC curve (AUC) was analysed to estimate the effectiveness of LINC00978 for prediction.
All P values were 2-sided. Differences were considered as statistically V = length × width 2 ∕2(mm 3 )
significant for P values less than 0.05. Data were presented as mean with the standard deviation (SD).
| RESULTS
| LINC00978 is upregulated in gastric cancer tissues and cell lines
The expression levels of LINC00978 in human gastric cancer tissues were analysed by using the microarray data downloaded from GEO (GSE13911 and GSE79973). The results showed that LINC00978 expression level was consistently upregulated in GSE13911 and GSE79973 datasets from either unpaired or paired samples ( Figure 1A,B) . To validate the findings of GEO data analysis, we examined LINC00978 expression in a cohort of 72 paired gastric cancer and adjacent non-cancerous tissues by using qRT-PCR.
The expression level of LINC00978 was significantly upregulated in gastric cancer tissues compared with the paired non-cancerous tissues (P < 0.001, Figure 1C,D) . We further analysed the relationship between LINC00978 expression level and the clinicopathological features of gastric cancer patients. As shown in Table 1 , the expression level of LINC00978 was associated with tumour size (P < 0.05), lymphatic metastasis (P < 0.01) and TNM stage (P < 0.01). The area under ROC curve (AUC) was 0.746 (95% confidence interval (CI)= 0.663-0.828, P < 0.001; Figure 1E ). The sensitivity and specificity were 0.53 and 0.92, respectively. Moreover, 5 cell lines including one normal gastric epithelial cell line GES-1 and 4 gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, HGC-27) were detected for LINC00978 expression. The expression levels of LINC00978 in MGC-803, BGC-823, SGC-7901 and HGC-27 cells were significantly higher than that in GES-1 cells ( Figure 1F ). Taken together, these findings suggest that LINC00978 is upregulated in gastric cancer tissues and cell lines.
| LINC00978 expression level is elevated in the serum of gastric cancer patients
We further tested the expression of LINC00978 in serum samples from gastric cancer patients and healthy controls. The results
showed that the expression levels of serum LINC00978 were significantly higher in gastric cancer patients than those in healthy controls ( Figure 1G) . Furthermore, the AUC of ROC curve was 0.831 (95% CI 0.754-0.908, sensitivity 0.80, specificity 0.70), as shown in Figure 1H .
In summary, these data suggest that LINC00978 is highly expressed in the circulation of gastric cancer patients and may serve as a potential biomarker for gastric cancer.
| LINC00978 silencing inhibits gastric cancer cell growth in vitro and in vivo
To investigate the roles of LINC00978 in gastric cancer, we inhibited LINC00978 expression in gastric cancer cells by using shRNAmediated interference (Figure 2A ). The proliferation abilities of gastric cancer cells were determined by using cell counting and colony formation assays. As shown in Figure 2B , the silencing of LINC00978
significantly retarded the growth of gastric cancer cells. The results of colony formation assay showed that gastric cancer cells with LINC00978 knockdown formed significantly less colonies than control cells (P < 0.001, Figure 2C ). The effect of LINC00978 on gastric cancer growth in vivo was determined by using a subcutaneous xenograft tumour model in mice. The results showed that the mice injected with sh-LINC00978 gastric cancer cells developed smaller tumours than that injected with sh-control cells (P < 0.001, Figure 2D ). The results of immunohistochemical staining further revealed that there were less Ki-67 positive proliferating cells in the tumour tissues from mice in sh-LINC00978 group than that in sh-control group ( Figure 2E ).
Thus, these findings indicate that LINC00978 could promote gastric cancer growth in vitro and in vivo.
| LINC00978 knockdown induces cell cycle arrest and apoptosis in gastric cancer cells
To further explore the potential mechanisms by which LINC00978
could affect gastric cancer cell proliferation, we performed flow cytometric analyses to determine the cell cycle distribution and apoptosis of gastric cancer cells with or without LINC00978 knockdown. The results of cell cycle analysis revealed that LINC00978 knockdown led to a significant increase in the proportion of cells in G1 phase (P < 0.05) while a significant decrease in the percentage of cells in S phase (P < 0.01), both in MGC-803 and SGC-7901 cells ( Figure 3A) . We further performed Annexin-V/PI double staining combined with flow cytometric analysis to evaluate the effect of LINC00978 knockdown on cell apoptosis. As shown in indicate that LINC00978 knockdown could inhibit gastric cancer cell proliferation by inducing cell cycle arrest and apoptosis.
| LINC00978 knockdown inhibits the migration and invasion of gastric cancer cells
We next wanted to know whether LINC00978 knockdown affected the metastatic potential of gastric cancer cells. The results of transwell migration assay showed that LINC00978 knockdown inhibited the migration abilities of both MGC-803 and SGC-7901 cells ( Figure 4A ). In addition, the depletion of LINC00978 also suppressed the invasion abilities of gastric cancer cells as shown by matrigel invasion assays ( Figure 4B ). These findings suggest that LINC00978 may enhance gastric cancer metastasis through the promotion of cell migration and invasion.
| LINC00978 knockdown inhibits the activation of TGF-β/SMAD pathway and suppresses EMT in gastric cancer cells
To elucidate the mechanisms that are responsible for the inhibitory role of LINC00978 in gastric cancer cell migration and invasion, we 
| DISCUSSION
LINC00978 was first identified in a microarray analysis as one of the mostly altered lncRNAs by resveratrol in lung cancer cells. 17 Further study revealed that LINC00978 can be used as a potential biomarker to predict prognosis in breast cancer patients. 18 Recently, LINC00978 was reported as one of the 4 serum lncRNAs that might serve as a panel for gastric cancer diagnosis. 19 However, the biological functions and potential underlying mechanisms of LINC00978 in gastric cancer progression remain unclear.
In this study, we first identified LINC00978 as an overexpressed lncRNA in gastric cancer by analysing GEO microarray datasets. We at G1 phase. 17 We found that LINC00978 knockdown also resulted in G1 phase arrest in gastric cancer cells, leading to the inhibition of proliferation. LINC00978 is suggested to regulate multiple cell cycleassociated genes in lung cancer cells. 17 We showed that LINC00978 knockdown upregulated the expression of p21, an important cell cycle regulator, indicating that LINC0097 is critically involved in the regulation of cell cycle progression. We also showed that LINC00978 knockdown induced apoptosis in gastric cancer cells, suggesting that LINC00978 may also promote gastric cancer cell proliferation by protecting them from apoptosis. In support of the in vitro findings, our in vivo animal study data also showed that the tumours generated with sh-LINC00978 transfected cells had smaller volumes and weights, indicating that the knockdown of LINC00978 inhibits gastric tumour growth in vivo.
About 90% of cancer deaths are caused by metastases in distant organs, making metastasis the major cause of mortality in patients with cancer. 20 Deng et al. compared the expression levels of LINC00978 between low-metastatic and high-metastatic breast cancer cell lines and found that LINC00978 expression levels were significantly higher in the high-metastatic cell lines than in the lowmetastasis cell lines. 18 However, there was no correlation between LINC00978 expression level and lymph node status in breast cancer patients. 18 In this study, we demonstrated that LINC00978 expression level was closely associated with lymphatic metastasis in gastric cancer patients. We further performed functional studies to confirm the potential of LINC00978 in cancer metastasis. Our results revealed that the migration and invasion abilities of gastric cancer cells were significantly inhibited by LINC00978 knockdown.
EMT plays a central role in driving cancer metastasis. Many transcription factors can activate EMT, including ZEB, Twist and Snail families. [21] [22] [23] We found that LINC00978 knockdown inhibited the expression of Twist1 and Slug (Snail2), leading to the downregulation of N-cadherin and vimentin but the upregulation of E-cadherin, indicating that LINC00978 may promote the metastatic potential of gastric cancer cell by inducing EMT. Oncogenic signals, growth factors and inflammatory and hypoxic microenvironment can trigger EMT. [24] [25] [26] TGF-β is one of the best-studied drivers of EMT. 27 We showed that LINC00978 knockdown inhibited the expression of TGF-β and suppressed the activation of SMAD2 and the expression of MMP9 in gastric cancer cells, suggesting that LINC00978 may promote EMT through the regulation of TGF-β/SMAD pathway.
However, the detailed mechanism by which LINC00978 affects TGF-β/SMAD pathway warrants further investigation.
In conclusion, we demonstrated in this study the expression pattern, biological function and potential mechanism of LINC00978 in gastric cancer. Our findings partially unveil the roles of LINC00978 in gastric cancer and provide a potential biomarker for the diagnosis and prognosis of gastric cancer.
